Summary sheet
The project supports the Promoter's research and development (R&D) investments to progress a pipeline of new therapeutics across the pharmaceutical value-chain.
R&D investments concern pediatric-friendly therapeutics adressing critical unmet medical needs in the field of rare and orphan diseases across the pharmaceutical value-chain.
R&D investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The project promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.